| Schedule of Revenues Disaggregated by Category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2026 |
|
2025 |
|
2026 |
|
2025 |
| Product sales: |
|
|
|
|
|
|
|
| Gross product sales |
$ |
93,603 |
|
|
$ |
85,624 |
|
|
$ |
257,455 |
|
|
$ |
225,508 |
|
| Discounts and allowances |
(21,314) |
|
|
(21,557) |
|
|
(63,228) |
|
|
(58,943) |
|
| Total product sales, net |
72,289 |
|
|
64,067 |
|
|
194,227 |
|
|
166,565 |
|
| Contract revenues from collaborations and other: |
|
|
|
|
|
|
|
| Release of cost share liability |
— |
|
|
— |
|
|
— |
|
|
39,981 |
|
|
|
|
|
|
|
|
|
| Milestone revenue |
— |
|
|
— |
|
|
4,000 |
|
|
3,000 |
|
| Delivery of drug supplies, royalties and others |
8,601 |
|
|
5,395 |
|
|
20,184 |
|
|
14,934 |
|
| Total contract revenues from collaborations and other |
8,601 |
|
|
5,395 |
|
|
24,184 |
|
|
57,915 |
|
|
|
|
|
|
|
|
|
| Total revenues |
$ |
80,890 |
|
|
$ |
69,462 |
|
|
$ |
218,411 |
|
|
$ |
224,480 |
|
|
| Schedule of Product Revenue Allowance and Reserve Categories |
The following tables summarize activity in chargebacks, discounts and fees, government and other rebates, and returns included in revenue reserves and refund liabilities for each of the periods presented (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks,
Discounts and
Fees |
|
Government
and Other
Rebates |
|
Returns |
|
Total |
| Balance at January 1, 2026 |
$ |
12,519 |
|
|
$ |
10,389 |
|
|
$ |
4,808 |
|
|
$ |
27,716 |
|
| Provision related to current period sales |
50,502 |
|
|
15,683 |
|
|
1,885 |
|
|
68,070 |
|
| Adjustment related to prior period sales |
(3,260) |
|
|
(2,362) |
|
|
— |
|
|
(5,622) |
|
| Credit or payments made during the period |
(49,672) |
|
|
(12,356) |
|
|
(1,327) |
|
|
(63,355) |
|
| Balance at September 30, 2026 |
$ |
10,089 |
|
|
$ |
11,354 |
|
|
$ |
5,366 |
|
|
$ |
26,809 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks,
Discounts and
Fees |
|
Government
and Other
Rebates |
|
Returns |
|
Total |
| Balance at January 1, 2025 |
$ |
13,374 |
|
|
$ |
8,343 |
|
|
$ |
4,723 |
|
|
$ |
26,440 |
|
| Provision related to current period sales |
40,399 |
|
|
14,261 |
|
|
1,921 |
|
|
56,581 |
|
| Adjustment related to prior period sales |
(307) |
|
|
(1,287) |
|
|
(1,357) |
|
|
(2,951) |
|
| Credit or payments made during the period |
(40,673) |
|
|
(8,950) |
|
|
(427) |
|
|
(50,050) |
|
| Balance at September 30, 2025 |
$ |
12,793 |
|
|
$ |
12,367 |
|
|
$ |
4,860 |
|
|
$ |
30,020 |
|
|
| Schedule of Revenues From Product Sales Disaggregated by Customers |
The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations and other:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2026 |
|
2025 |
|
2026 |
|
2025 |
| McKesson Corporation |
44 |
% |
|
48 |
% |
|
46 |
% |
|
39 |
% |
| Cencora, Inc. |
22 |
% |
|
23 |
% |
|
22 |
% |
|
17 |
% |
| Cardinal Health, Inc. |
10 |
% |
|
10 |
% |
|
10 |
% |
|
* |
| OncoMed Specialty, LLC |
12 |
% |
|
— |
|
|
11 |
% |
|
— |
|
| Optime Care, Inc. |
— |
|
|
11 |
% |
|
— |
|
|
* |
| Lilly |
— |
|
|
— |
|
|
— |
|
|
18 |
% |
|
|
|
|
|
|
|
|
______________________________________________________________________
*Denotes less than 10%
|